Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) is a dataset published in Alzheimer s & Dementia (2023). On theSindex it has a DataRank of 0.663, placing it in the top 30.1% of the data-sharing corpus. It has been cited 82 times.
Ranks in the top 30% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.663
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Alzheimer's Association
Grant: ZEN‐21‐848216
NIA NIH HHS
Grant: U24 AG021886
NIA NIH HHS
Grant: P30 AG066546
NIA NIH HHS
Grant: P30 AG072980
NIA NIH HHS
Grant: R01 AG075827
NINDS NIH HHS
Grant: R21 NS120629
NIA NIH HHS
Grant: P30 AG062422
NIA NIH HHS
Grant: P30 AG072979
NIA NIH HHS
Grant: R35 AG072362
NIA NIH HHS
Grant: U01 AG057195
NIA NIH HHS
Grant: R01 AG072120
NIA NIH HHS
Grant: R01 AG087250
NINDS NIH HHS
Grant: U19 NS110456
NIA NIH HHS
Grant: R01 AG079170
NIA NIH HHS
Grant: R56 AG057195
NIA NIH HHS
Grant: P30 AG072977
Alzheimer's Association
Grant: ZEN-21-848216
NIA NIH HHS
Grant: P30 AG066530
National Institutes of Health
Grant: 5R21NS120629-02
In Vivo Detection of Chronic Traumatic Encephalopathy with 18F-MK-6240 Tau PET
National Institutes of Health
Grant: 5U19NS110456-04
Center without Walls for Imaging Proteinopathies with PET (CW2IP2)
National Institutes of Health
Grant: 5P30AG062422-03
New Approaches to Dementia Heterogeneity
National Institutes of Health
Grant: 5U01AG057195-05
Early Onset AD Consortium - the LEAD Study (LEADS)
National Institutes of Health
Grant: 5R35AG072362-02
Reimagining Precision Medicine Approaches to AD Diagnosis
FWCI
0.00
Citation Percentile
0.0%
Influential Citations
3
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 1 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 2 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 2 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 3 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 3 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 4 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 4 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 5 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 5 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 6 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 7 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 6 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 7 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 8 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 8 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 9 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 9 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 10 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Additional file 10 of Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease